Medirom Healthcare reports FY24 EPS 17c vs. 15c last year

Reports revenue $52.7M vs. $43.4M last year. “Thus far in 2025, MEDIROM has announced several notable developments,” said CEO Koji Eguchi. “In January, the Company’s subsidiary, MEDIROM MOTHER Labs Inc., began providing its remote health monitoring system, REMONY, and charging-free smart tracker device, MOTHER Bracelet, to the Electronics Division of TOPPAN Inc. Also in January, all corporate capital registration procedures under Japanese law were completed with respect to the Company’s offering of 2,860,000 common shares represented by American Depositary Shares, generating gross proceeds of approximately $5M. In March, Yasuhiro Hayami, Chief Business Officer of MEDIROM Mother Labs, made a second investment in Mother Labs’ Series A financing at a pre-money valuation of approximately $60M. This new investment followed Mr. Hayami’s initial investment in a Series A financing in December 2024. Also in March, MEDIROM obtained a new unsecured short-term bank loan in the amount of approximately $2.4M, which is being used for repayment of indebtedness to MEDIROM Mother Labs and for general working capital, including MOTHER Bracelet development.” Looking forward to the rest of 2025, Eguchi said that MEDIROM “will continue to strive to improve revenue growth and bottom-line performance for the year. As for near-term goals, we aim to not only to capture a significant share of the existing Japanese market for relaxation salons but also to expand our Digital Preventative Healthcare business lines through a variety of strategic initiatives and to increase the margin in that segment. As part of this, we intend to increase the number of Lav users via the Specific Health Guidance Program promoted by the Ministry of Health, Labor and Welfare of Japan and expand the billing user base for the upgraded Lav application. We also intend to accelerate the production of our MOTHER Bracelet for large orders from corporate clients.”